ClinicalTrials.Veeva

Menu

A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis

H

Hospital Authority, Hong Kong

Status

Completed

Conditions

Peritonitis

Treatments

Drug: Intraperitoneal Cefepime

Study type

Observational

Funder types

Other

Identifiers

NCT00497744
KW/EX/05-020
HARECCTR0500027

Details and patient eligibility

About

Cefepime is a broad-spectrum antibiotic used in treating CAPD peritonitis. However, medical knowledge has been lacking with regard to its pharmacokinetic profile after it has been administered intraperitoneally. The current study aims at determining the drug level at different time after the drug has been added into the peritoneal fluid in patients with CAPD peritonitis. The results of this study will finally leads to rational prescription of this drug at correct dosages.

Enrollment

6 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >= 18 years & has been put on CAPD for >= 4 weeks before entering into the study

Exclusion criteria

  • Known hypersensitivity to cefepime or other cephalosporin; CAPD peritonitis <= 28 days before being enrolled into the study
  • Antibiotic treatment within 1 week prior to entry into the study
  • Severe exit site or tunnel infection on the day of presentation
  • Any conditions that prompt early removal of Tenckhoff catheter irrespective of clinical response to antibiotic treatment
  • Abdominal malignancy; Any surgical causes of peritonitis
  • Suspected or known fungal or tuberculous peritonitis
  • History of dementia or known mental incompetency

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems